相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation
Roberta Leonardi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
S. Negrotto et al.
LEUKEMIA (2012)
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase
Amir T. Fathi et al.
LEUKEMIA RESEARCH (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
Yang Shen et al.
BLOOD (2011)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome
Celeste Bello et al.
CANCER (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia
Lars Bullinger et al.
BLOOD (2010)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Susanne Schnittger et al.
BLOOD (2010)
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
Claire L. Green et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
Adedayo Oke et al.
CANCER RESEARCH (2009)
Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
Aaron D. Schimmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
Elisabeth Walsby et al.
HAEMATOLOGICA (2008)
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
J. Pedersen-Bjergaard et al.
LEUKEMIA (2008)
Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome
Fernando Callera et al.
LEUKEMIA RESEARCH (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics:: are we ready for a prognostically prioritized molecular classification?
Krzysztof Mrozek et al.
BLOOD (2007)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling
LH Olesen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Global approach to the diagnosis of leukemia using gene expression profiling
T Haferlach et al.
BLOOD (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion
J Libura et al.
BLOOD (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
Risk assessment in patients with acute myeloid leukemia and a normal karyotype
M Bienz et al.
CLINICAL CANCER RESEARCH (2005)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
MG Mohi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Aurora kinases link chromosome segregation and cell division to cancer susceptibility
P Meraldi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2004)
Epigenetic regulation of tumor suppressors in t(8:21)-containing AML
GY Yang et al.
ANNALS OF HEMATOLOGY (2004)
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
MA Sekeres et al.
BLOOD (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
W Fiedler et al.
BLOOD (2003)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor
SW Hiebert et al.
BLOOD CELLS MOLECULES AND DISEASES (2003)
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia:: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
EH Estey et al.
BLOOD (2001)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
AF List et al.
BLOOD (2001)
Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
A Wahlin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
JM Amann et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications
V Santini et al.
ANNALS OF INTERNAL MEDICINE (2001)
Topoisomerase II inhibitor-related acute myeloid leukaemia
CH Pui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
